RxDoctor Payments DataLook up a doctor →

Patricia Moesner, MD

Anesthesiology · Brownstown Twp, MINPI 1013127893

Payments from drug & device makers

$13,932in general payments, 2019–2025

Across 616 payments — averaging $22.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$2K
  • Amgen$1K
  • AbbVie$1K
  • Scilex Pharmaceuticals Inc.$789
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$751
  • Collegium Pharmaceutical, Inc.$712
  • plus $7K from 45 others

What the payments were for

  • Travel & lodging$570%
  • Food & beverage$13,870100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,932 in reported general payments places this provider in the 95th percentile of 1,299 anesthesiology providers in Michigan.

See all anesthesiology providers in Michigan

Medicare billing

Part B allowed, 2024
$332,959
Medicare patients
527
Services billed
15,057

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl46$27,645
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl89$10,474
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen723$10,054
MovantikNaloxegol Oxalate24$9,601
Pregabalin299$8,476
Buprenorphine33$7,980
Aimovig AutoinjectorErenumab-Aooe11$7,635
Gabapentin303$6,482
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen340$6,201
SuboxoneBuprenorphine Hcl/Naloxone Hcl11$4,977
Fentanyl49$3,910
Morphine Sulfate ErMorphine Sulfate67$1,824
Lidocaine22$1,536
Celecoxib38$1,429
Tizanidine Hcl132$1,256

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$712$27,64546 claims
Redhill Biopharma Inc.Movantik$130$9,60124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,299 anesthesiology providers in Michigan.

Other anesthesiology in Brownstown Twp

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →